Grifols to evaluate potential U.S. IPO for part of Biopharma business, but retaining control of listed subsidiary
Renta 4 | According to a regulatory filing, the Board of Directors will begin evaluating a potential U.S. IPO of a minority stake in Grifols Biopharma US. The parent company would remain listed in Spain and retain control of the U.S. business. The transaction would allow the company to raise capital to strengthen the group’s balance sheet and reduce debt (which stood at 4.2x debt-to-EBITDA at the end of 2025)….
Read More
